Vimarsana
Biggest News Aggregation in the World

Chipscreen Biosciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Chipscreen Biosciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Chipscreen Biosciences Today - Breaking & Trending Today

National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma - Vimarsana News

National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma

Published: April 30, 2024

/PRNewswire/ -- Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company's lead innovative...

Source: prnewswire.com
Related Topics:
Feng WangUnited StatesRuihua XuSun YatXianping LuChidamide TucidinostatChipscreen BiosciencesWeili ZhaoChidamide EpidazaData Monitoring CommitteeChipscreen Biosciences United States Co LtdPrnewswire Shenzhen Chipscreen Biosciences Co LtdChengdu Small Molecule Early Rd CenterShanghai Jiao Tong University School Of MedicineChengdu Regional Head Office Rd CenterShenzhen Chipscreen Biosciences Co LtdShenzhen Small Molecule Early Rd CenterInnovative Drug DevelopmentShenzhen Head Office Rd CenterNational ScienceTreatment CenterNational Medical Products AdministrationAmerican Society Of Clinical OncologyShanghai BranchStock Symbol
Chidamide Plus R-CHOP Approved in China for MYC/BCL2–Expressing DLBCL - Vimarsana News

Chidamide Plus R-CHOP Approved in China for MYC/BCL2–Expressing DLBCL

Published: April 30, 2024

Chidamide plus R-CHOP has received approval from China’s NMPA for the management of diffuse large B-cell lymphoma.

Source: onclive.com
Related Topics:
Chipscreen BiosciencesXianping LuChina National Medical Products AdministrationLymphoma International Prognosis IndexData Monitoring CommitteeNational Medical Products AdministrationIndependent Data Monitoring CommitteeLugano ClassificationDiffuse Largeb Cell LymphomaR Chop
Non-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 - Vimarsana News

Non-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032

Published: January 17, 2024

/PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices,...

Source: prnewswire.com
Related Topics:
United StatesUnited KingdomHightide BiopharmaEli LillyNovo NordiskPrnewswire DelveinsightShruti ThakurMadrigal PharmaFite BiopharmaTanabe PharmaRedx PharmaAramchol MeglumineBristol Myers SquibbEnyo PharmaInventiva PharmaFalk Pharma GmbChipscreen BiosciencesSagimet BiosciencesNusirt BiopharmaCytodyn IncGilead SciencesOasis PharmaceuticalsGalectin Therapeutics IncKey CompaniesNeuraly Inc
Chipscreen NewWay: First Patient Dosed in Phase 1 Trial of the Bispecific Antibody NWY001, a Next-generation Tumor Immunotherapy in Patients with Advanced Solid Tumors - Vimarsana News

Chipscreen NewWay: First Patient Dosed in Phase 1 Trial of the Bispecific Antibody NWY001, a Next-generation Tumor Immunotherapy in Patients with Advanced Solid Tumors

Published: January 16, 2024

/PRNewswire/ -- Chengdu Chipscreen NewWay Biosciences Co., Ltd. (NewWay) announced that on January 5, 2024, the dosing of the first patient for a phase I...

Source: prnewswire.com
Related Topics:
Hong KongUnited StatesSan FranciscoChipscreen Newway BiosciencesChipscreen NewwayHaimen JiangsuChipscreen BiosciencesChipscreen Biosciences United StatesShenzhen Chipscreen Pharmaceuticals Co LtdShanghai Business CenterBiocytogen Pharmaceuticals Beijing Co LtdPrnewswire Chengdu Chipscreen Newway Biosciences Co LtdShenzhen Chipscreen Biosciences Co LtdSun Yat Sen University Cancer CenterChengdu Chipscreen Pharmaceuticals Co LtdEucure Beijing Biopharma Co LtdChengdu Chipscreen Newway Biosciences Co LtdClinical Research CenterBin LiuScientific DirectorGreater ChinaMainland ChinaChengdu Hi Tech ZoneGenomics Based Integrated Drug DiscoveryEarly Evaluation
Hematopoietic Stem Cell Transplantation Market to Grow Rapidly During the Study Period (2019-2032), Evaluates DelveInsight - Vimarsana News

Hematopoietic Stem Cell Transplantation Market to Grow Rapidly During the Study Period (2019-2032), Evaluates DelveInsight

Published: January 8, 2024

/PRNewswire/ -- DelveInsight's Hematopoietic Stem Cell Transplantation Market Insights report includes a comprehensive understanding of current treatment...

Source: prnewswire.com
Related Topics:
United StatesUnited KingdomAbbvie TeneooneRoche GenentechShruti ThakurPrnewswire DelveinsightJohnson JanssenKronos BioHeidelberg PharmaBristol Myers SquibbXynomic Pharmaceuticals IncForge Biologics IncInc Incyte CorporationAntengene TherapeuticsPacylex PharmaceuticalsMerck Sharp DohmeTimmune Biotech IncMiltenyi Biotec IncTeneobio IncBiosciences IncKey Hematopoietic Stem Cell Transplantation CompaniesBioscience InternationalSeres Therapeutics IncKey CompaniesJiangsu Hengrui Medicine Co Ltd